First-generation paclitaxel- vs. second-generation zotarolimus-eluting stents in small coronary arteries: the BASKET-SMALL Pilot Study

Raban Jeger; Matthias Pfisterer; Otmar Pfister; Peter Rickenbacher; Michael Handke; Nicole Gilgen; Michael Coslovsky; Christoph Kaiser

doi:10.5114/aic.2016.63630

eISSN: 1897-4295
ISSN: 1734-9338

Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej

Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

4/2016
vol. 12

Send email

Copy url:

abstract:

Original paper

First-generation paclitaxel- vs. second-generation zotarolimus-eluting stents in small coronary arteries: the BASKET-SMALL Pilot Study

Raban Jeger

,

Matthias Pfisterer

,

Otmar Pfister

,

Peter Rickenbacher

,

Michael Handke

,

Nicole Gilgen

,

Michael Coslovsky

,

Christoph Kaiser

Adv Interv Cardiol 2016; 12, 4 (46): 314–320

DOI: https://doi.org/10.5114/aic.2016.63630

Online publish date: 2016/11/17

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Jeger R, Pfisterer M, Pfister O, et al. First-generation paclitaxel- vs. second-generation zotarolimus-eluting stents in small coronary arteries: the BASKET-SMALL Pilot Study. Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej. 2016;12(4):314-320. doi:10.5114/aic.2016.63630.

APA

Jeger, R., Pfisterer, M., Pfister, O., Rickenbacher, P., Handke, M.,  & Gilgen, N. et al. (2016). First-generation paclitaxel- vs. second-generation zotarolimus-eluting stents in small coronary arteries: the BASKET-SMALL Pilot Study. Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej, 12(4), 314-320. https://doi.org/10.5114/aic.2016.63630

Chicago

Jeger, Raban, Matthias Pfisterer, Otmar Pfister, Peter Rickenbacher, Michael Handke, Nicole Gilgen,  and Michael Coslovsky et al. 2016. "First-generation paclitaxel- vs. second-generation zotarolimus-eluting stents in small coronary arteries: the BASKET-SMALL Pilot Study". Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej 12 (4): 314-320. doi:10.5114/aic.2016.63630.

Harvard

Jeger, R., Pfisterer, M., Pfister, O., Rickenbacher, P., Handke, M., Gilgen, N., Coslovsky, M.,  and Kaiser, C. (2016). First-generation paclitaxel- vs. second-generation zotarolimus-eluting stents in small coronary arteries: the BASKET-SMALL Pilot Study. Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej, 12(4), pp.314-320. https://doi.org/10.5114/aic.2016.63630

MLA

Jeger, Raban et al. "First-generation paclitaxel- vs. second-generation zotarolimus-eluting stents in small coronary arteries: the BASKET-SMALL Pilot Study." Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej, vol. 12, no. 4, 2016, pp. 314-320. doi:10.5114/aic.2016.63630.

Vancouver

Jeger R, Pfisterer M, Pfister O, Rickenbacher P, Handke M, Gilgen N et al. First-generation paclitaxel- vs. second-generation zotarolimus-eluting stents in small coronary arteries: the BASKET-SMALL Pilot Study. Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej. 2016;12(4):314-320. doi:10.5114/aic.2016.63630.

Introduction: Event rates after percutaneous coronary interventions (PCI) are higher in small than large coronary vessels but may vary between different drug-eluting stent (DES) types.

Aim: To assess the efficacy of two different DES in small vessel disease.

Material and methods: Patients with small vessel PCI were randomised 1 : 1 to a first-generation paclitaxel- vs. a second-generation zotarolimus-eluting stent. The primary endpoint was a composite of cardiac death, non-fatal myocardial infarction, and target vessel revascularisation after 2 years.

Results: Overall, 191 patients were enrolled: 100 with a paclitaxel- and 91 with a zotarolimus-eluting stent. Baseline characteristics were similar in both groups. After 2 years, rates of the primary endpoint were numerically higher for zotarolimus- than paclitaxel-eluting stents (9.9% vs. 5.0%, hazard ratio 2.09, 95% confidence interval (CI) 0.7–6.2, p = 0.19), which was mainly driven by higher rates of target vessel revascularisation (6.6% vs. 2.0%, hazard ratio 3.39, 95% CI: 0.68–16.78, p = 0.14). Based on this, a total of 1,019 patients would be necessary to demonstrate at least non-inferiority between the DES used.

Conclusions: In this pilot study, paclitaxel-eluting stents had a favourable efficacy profile in small vessel disease, although the numbers were too small to draw final conclusions. Based on the prohibitively high sample size for a randomized controlled trial between DES, other treatment options should be considered.

keywords:

First-generation paclitaxel- vs. second-generation zotarolimus-eluting stents in small coronary arteries: the BASKET-SMALL Pilot Study

Raban Jeger , Matthias Pfisterer , Otmar Pfister , Peter Rickenbacher , Michael Handke , Nicole Gilgen , Michael Coslovsky , Christoph Kaiser

small vessel disease, drug-eluting stent, paclitaxel, zotarolimus

Raban Jeger

,

Matthias Pfisterer

,

Otmar Pfister

,

Peter Rickenbacher

,

Michael Handke

,

Nicole Gilgen

,

Michael Coslovsky

,

Christoph Kaiser